Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023473 (
chronic myeloid leukemia
)
18,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Receptor-binding cancer antigen expressed on SiSo cells (
RCAS1
) is a secreted antigen that induces apoptosis in putative receptor-expressing cells, including peripheral lymphocytes and natural killer (NK) cells.
RCAS1
expression is associated with aggressive characteristics and poor overall survival for 15 different human malignancies. The putative
RCAS1
receptor has not been isolated and the mechanism of
RCAS1
apoptosis induction remains unclear. This study explores how
RCAS1
is involved in apoptosis initiation. The cell lines SiSo and MCF-7, human uterine carcinoma and breast adenocarcinoma, respectively, both express
RCAS1
, but
RCAS1
secretion is undetectable in MCF-7 cells. SiSo and MCF-7 cells were stimulated to induce
RCAS1
ectodomain shedding followed by assessment of
RCAS1
expression and secretion. Additionally, the
RCAS1
putative receptor-expressing human
chronic myelogenous leukemia
cell line K562 was co-cultured with SiSo, MCF-7, or soluble
RCAS1
to follow
RCAS1
secretion in apoptosis initiation.
RCAS1
secretion was strongly suppressed by inhibitors of metalloproteases, protein kinase C (PKC)-delta, mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase (MEK), epidermal growth factor (EGF), and G-protein-coupled receptor (GPCR). K562 apoptosis could be induced only by co-culturing with SiSo or soluble
RCAS1
.
RCAS1
is thus secreted by ectodomain shedding, which may represent a pivotal step in
RCAS1
-induced apoptosis initiation.
...
PMID:Receptor-binding cancer antigen expressed on SiSo cells induces apoptosis via ectodomain shedding. 2007 34